コンテンツへスキップ
Merck

Y0001593

デキサメタゾン

European Pharmacopoeia (EP) Reference Standard

別名:

(11β,16α)-9-フルオロ-11,17,21-トリヒドロキシ-16-メチルプレグナ-1,4-ジエン-3,20-ジオン, 9α-フルオロ-16α-メチル-11β,17α,21-トリヒドロキシ-1,4-プレグナジエン-3,20-ジオン, 9α-フルオロ-16α-メチルプレドニゾロン, プレドニゾロンF

ログインで組織・契約価格をご覧ください。

サイズを選択してください

表示を変更する

この商品について

実験式(ヒル表記法):
C22H29FO5
CAS番号:
分子量:
392.46
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
MDL number:
Beilstein/REAXYS Number:
2066651
テクニカルサービス
お困りのことがあれば、経験豊富なテクニカルサービスチームがお客様をサポートします。
お手伝いします


biological source

synthetic

grade

pharmaceutical primary standard

agency

EP

API family

dexamethasone

form

powder

manufacturer/tradename

EDQM

storage condition

protect from light

mp

262-264 °C

solubility

water: <0.1 g/L

application(s)

pharmaceutical (small molecule)

format

neat

shipped in

ambient

storage temp.

2-8°C

SMILES string

C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO

InChI

1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1

InChI key

UREBDLICKHMUKA-CXSFZGCWSA-N

Gene Information

human ... NR3C1(2908)

General description

Dexamethasone belongs to the class of synthetic glucocorticoid steroid drugs.
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Dexamethasone is used as an EP referencs standard to quantify the analyte in pharmaceutical formulations using liquid chromatography (LC) technique.

Biochem/physiol Actions

グルココルチコイド・抗炎症剤。T細胞の生存、成長、分化を調節します。一酸化窒素合成酵素の誘導を阻害します。
グルココルチコイド抗炎症薬です。

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.


pictograms

Health hazard

signalword

Danger

hcodes

Hazard Classifications

Repr. 1B

保管分類

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable



最新バージョンのいずれかを選択してください:

試験成績書(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 資料 section.

サポートが必要な場合は、お問い合わせください カスタマーサポート

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする



S Choi et al.
British journal of anaesthesia, 112(3), 427-439 (2014-01-15)
Brachial plexus nerve blocks (BPBs) have analgesic and opioid sparing benefits for upper extremity surgery. Single-injection techniques are limited by the pharmacological duration and therapeutic index of local anaesthetics (LAs). Continuous catheter techniques, while effective can present management challenges. Off-label
Sara Bringhen et al.
Blood, 124(1), 63-69 (2014-05-24)
This multicenter, open-label phase 2 trial determined the safety and efficacy of carfilzomib, a novel and irreversible proteasome inhibitor, in combination with cyclophosphamide and dexamethasone (CCyd) in patients with newly diagnosed multiple myeloma (NDMM) ≥65 years of age or who
A Keith Stewart et al.
The New England journal of medicine, 372(2), 142-152 (2014-12-09)
Lenalidomide plus dexamethasone is a reference treatment for relapsed multiple myeloma. The combination of the proteasome inhibitor carfilzomib with lenalidomide and dexamethasone has shown efficacy in a phase 1 and 2 study in relapsed multiple myeloma. We randomly assigned 792